Severe gastrointestinal tract (GIT) complications induced by radiotherapy (RT) have been well documented in patients with systemic lupus erythematosus (SLE). SLE is a chronic, inflammatory, multi-system disease characterized by remissions and exacerbations. Its pathogenesis shows multiple, immunological aberrations characterized by polyclonal B-cell activation associated with abnormal expression of cytokines.\(^{[1,2]}\)

The use of RT in SLE patients has been considered to be a relative contraindication by many oncologists due to these patients' intolerance to radiation-induced side effects.\(^{[3-5]}\) In SLE patients, RT induces inflammatory reactions to the irradiated tissues, which lead to exacerbation of the inflammatory process. These radiation-induced side effects are related to the dose of RT and the volume of the irradiated normal tissue, thus, the goal of RT is to deliver an optimal dose to the tumor, with a minimal irradiated volume of normal tissues, including the GIT.\(^{[5]}\)

Intensity-modulated radiotherapy (IMRT) is a new radiotherapy technique that uses an inverse planning algorithm and allows radiation oncologists to be able to decide the exact dose of radiation to be delivered to the tumor and normal tissues.\(^{[6]}\)

**CASE REPORT**

A 32 year-old lady known to have SLE for eight years, and suffering from hypertension and grade IV lupus nephritis (proved by renal biopsy), presented with irregular vaginal bleeding and dysparaunia. Pelvic examination showed a bulky endocervical mass extending to the parametrium, but not reaching the pelvic wall, with an upper third vaginal wall extension. Biopsy revealed a high-grade squamous cell carcinoma. Thoracic, abdominal, and pelvic computed tomography (CT) and magnetic resonance imaging (MRI) confirmed the extension of the tumor to the lower uterine segment, which was associated with enlargement of the internal iliac pelvic lymph nodes without any evidence of metastasis. In addition, a bone scan was performed and showed no bony metastasis. Based on this work-up, the patient was diagnosed with stage IIB cervical cancer.

Her renal function was normal as proved by a renogram. Antinuclear antibody titer was 320, antiDNA antibody titer was 361, and other immunological study results were normal. Chemotherapy was contraindicated due to lupus nephropathy and surgery was not performed due to the extension and size of the tumor. Based on the contraindication to have neither surgery nor chemotherapy, the decision was made to treat her with RT. She received local 45 Gray (Gy) pelvic irradiation in 25 fractions (fx) over five weeks, 1.8 Gy/fx, with the IMRT technique. The radiation dose to the bowel was calculated to be as low as possible (see below).

The target volume and bowel were delineated with the aid of CT with contrast and fused MRI images as shown in Figure 1. The doses to the target and normal tissues were optimized.
as shown in Figure 2. The dose-volume histogram (DVH) showed a delivery of a 100% mean dose to the planning target volume (minimal dose 90% and maximal dose 108.5% as shown in Figure 3). The dose to the rectum ranges from 18.6 to 104.3% with a mean dose of 80%. The differential dose was $V_{45 Gy}$ (the rectal volume receiving > 45 Gy) < 1%, $V_{40 Gy}$ of 40%, and $V_{30 Gy}$ of 77%.

It is evident from the DVH that the small bowel dose ranges from 1 to 105.7% with a mean dose of 22.6%. The differential doses were $V_{45 Gy} = 0.4\%$, $V_{40 Gy} = 7.6\%$, and $V_{20 Gy} = 22\%$.

**Acute GIT toxicity**

The acute GIT side effects were graded and recorded using the common toxicity criteria modified by the National Cancer Institute of Canada (CTC-NCIC).[7] The gastrointestinal symptoms experienced were: i) nausea which was expected even in nonSLE patients in week 1 and that had disappeared at the end of the 1st week, ii) diarrhea which is the most worrisome expected side effect that started in the fourth week (after administering 36 Gy) and that was not more than four motions/day over the baseline (once daily). The rectal discomfort during defecation (GI proctitis) started to appear in week 5 as shown in Table 1.

**DISCUSSION**

It is challenging to use radiotherapy in SLE patients due to severe acute and late side effects.[8] In this case, the aim was to reduce the dose of radiation therapy to normal tissues

| Table 1: Gastrointestinal toxicity |
|-------------------------------|
| GIT toxicity | W1 | W2 | W3 | W4 | W5 |
| Nausea | G1 | G0 | G0 | G0 | G0 |
| Diarrhea | G0 | G0 | G0 | G1 | G1 |
| Proctitis | G0 | G0 | G0 | G0 | G1 |

W: week
and to give the prescribed dose to the tumor by using the IMRT technique, although there is limited experience in such cases. Most of the previously published studies showed that conventional radiotherapy induces acute and late GIT complications in SLE patients[8-10] with limited experience with the IMRT technique.[6]

In their review of the Michigan University experience, Lin and his colleagues showed that 86 patients had collagen vascular diseases and concluded that radiotherapy is associated with moderate side effects, but they were nevertheless not prohibitive for its use.[9] Furthermore, these results coincide with the Mayo Clinic data on 22 SLE patients that showed that whereas radiotherapy was well tolerated by these patients, it did carry a high risk of severe, late toxicity.[10]

This report reveals that decreasing the radiation dose to the normal tissues by using IMRT is associated with mild side effects. However, more data are needed to reach conclusions in the use of radiation therapy in patients with active connective tissue disease, including SLE.

REFERENCES

1. Krieg AM. CpG DN. A pathogenic factor in systemic lupus erythematosus? J Clin Immunol 1995;15:284-92.
2. Rose LM, Latchman DS, Isenberg DA. Bcl-2 and Fas, molecules which influence apoptosis: A possible role in systemic lupus erythematosus? Autoimmunity 1994;17:271-8.
3. Rathmell AJ, Taylor RE. Enhanced normal tissue response to radiation in a patient with discoid lupus erythematosus. Clin Oncol 1992;4:331-2.
4. Ross JG, Hussey DH, Mayr NA, Davis CS. Acute and late reactions to radiation therapy in patients with collagen vascular diseases. Cancer 1993;71:3744-52.
5. Olivetto IA, Fairey RN, Gillies JH, Stein H. Fatal outcome of pelvic radiotherapy for carcinoma of the cervix in a patient with systemic lupus erythematosus. Clin Radiol 1989;40:83-4.
6. Hartford AC, Palisca MG, Eichler TJ, Beyer DC, Devineni VR, Ibbott GS, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Intensity-Modulated Radiation Therapy (IMRT). Int J Radiat Oncol Biol Phys 2009;73:9-14.
7. Colevas AD, Setser A. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. J Clin Oncol 2004;22:543s.
8. Ho¨lscher T, Bentzen SM, Baumann M. Influence of connective tissue diseases on the expression of radiation side effects: A systematic review. Radiother Oncol 2006;78:123-30.
9. Lin A, Abu Isa E, Griffith KA, Ben-Josef E. Toxicity of radiotherapy in patients with collagen vascular disease. Cancer 2008;113:46-53.
10. Pinn ME, Gold DG, Miller RC, Petersen IA, Osborn TG. Radiotherapy for malignancy in patients with scleroderma: Systemic lupus erythematosus, radiotherapy, and the risk of acute and chronic toxicity: The Mayo Clinic experience. Int J Radiat Oncol Biol Phys 2008;71:498-506.

Source of Support: Nil, Conflict of Interest: None declared.